Effects of naloxone on nitrous oxide actions in healthy volunteers

Pain

Volumn 83, Issue 3, 1999, Pages 411-418

  Zacny, James P ^a   Conran, Aisling ^a   Pardo, Helene ^a   Coalson, Dennis W ^a   Black, Matthew ^a   Klock, P Allan ^a   Klafta, Jerome M ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Analgesia; Behavior; Naloxone; Nitrous oxide; Opioid; Pain

Indexed keywords

NALOXONE; NITROUS OXIDE;

ADULT; ANALGESIA; ANALGESIC ACTIVITY; ARTICLE; COLD PRESSOR TEST; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG SCREENING; FEMALE; HUMAN; HUMAN EXPERIMENT; INHALATIONAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; PAIN; PAIN ASSESSMENT; PRIORITY JOURNAL; PSYCHOMOTOR ACTIVITY;

ADMINISTRATION, INHALATION; ADULT; AFFECT; ANALGESIA; ANALGESICS, NON-NARCOTIC; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; NALOXONE; NARCOTIC ANTAGONISTS; NITROUS OXIDE; OXYGEN; PAIN MEASUREMENT; PSYCHOMOTOR PERFORMANCE;

EID: 0032703850     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3959(99)00127-X     Document Type: Article

References (59)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th :1994;American Psychiatric Association, Washington DC.
2. Berkowitz B., Ngai S.H. Nitrous oxide 'analgesia': resemblance to opiate action. Science. 194:1976;967-968.
3. Berkowitz B.A., Finck A.D., Ngai S.H. Nitrous oxide analgesia: reversal by naloxone and development of tolerance. J Pharmacol Exp Ther. 203:1977;539-546.
4. Buchsbaum M.S., Davis G.C., Bunney W.E. Naloxone alters pain perception and somatosensory evoked potentials in normal subjects. Nature. 270:1977;620-622.
5. Chapman C.R., Benedetti C. Nitrous oxide effects on cerebral evoked potential to pain: partial reversal with a narcotic antagonist. Anesthesiology. 51:1979;135-138.
6. Chen A.C., Dworkin S.F., Haug J. Human pain responsivity in a tonic pain model: physiological determinants. Pain. 37:1989;143-160.
7. Cohen M.R., Cohen R.M., Pickar D., Weingartner H., Murphy D.L. High-dose naloxone infusions in normals: dose-dependent behavioral, hormonal, and physiological responses. Arch Gen Psychiatry. 40:1983;613-619.
8. Cohen M.R., Cohen R.M., Weingartner H., Pickar D., Murphy D.L. High dose naloxone affects task performance in normal subjects. Psychiatry Res. 8:1983;127-136.
9. Czech D.A., Green D.A. Anxiolytic effects of nitrous oxide in mice in the light-dark and holeboard exploratory tests. Psychopharmacology. 109:1992;315-320.
10. Derogatis L.R., Lipman R.S., Covi L. HSCL-90: an outpatient psychiatric rating scale - a preliminary report. Psychopharmacol Bull. 9:1973;13-17.
11. Emmanouil D., Johnson C.H., Quock R.M. Nitrous oxide anxiolytic effect in mice in the elevated plus maze: mediation by benzodiazepine receptors. Psychopharmacology. 115:1994;167-172.
12. File S.E., Silverstone T. Naloxone changes self-ratings but not performance in normal subjects. Psychopharmacology. 74:1981;353-354.
13. Fraser H.F., van Horn G.G., Martin W.R., Wolbach A.B., Isbell H. Methods for evaluating abuse liability. (A) 'Attitude' of opiate addicts towards opiate-like drugs. (B) A short-term 'direct' addiction test. J Pharmacol Exp Ther. 133:1961;371-387.
14. Fukuhara N., Ishikawa T., Kinoshita H., Xiong L., Nakanishi O. Central nonadrenergic mediation of nitrous oxide-induced analgesia in rats. Can J Anaesth. 45:1998;1123-1129.
15. Gillman M.A., Lichtigfeld F.J. Opioid properties of psychotropic analgesic nitrous oxide (laughing gas). Perspect Biol Med. 38:1994;125-138.
16. Gracely R.H., Dubner R., Wolskee P.J., Deeter W.R. Placebo and naloxone can alter post-surgical pain by separate mechanisms. Nature. 306:1983;264-265.
17. Grevert P., Goldstein A. Effects of naloxone on experimentally induced ischemic pain and on mood in human subjects. Proc Natl Acad Sci (Wash). 74:1977;1291-1294.
18. Grevert P., Albert L.H., Goldstein A. Partial antagonism of placebo analgesia by naloxone. Pain. 16:1983;129-143.
19. Grevert P., Albert L.H., Inturrisi C.E., Goldstein A. Effects of eight-hour naloxone infusions on human subjects. Biol Psychiatry. 18:1983;1375-1392.
20. Grevert P., Goldstein A. Endorphins: naloxone fails to alter experimental pain or mood in humans. Science. 199:1978;1093-1095.
21. Grubman J., Woods J.H. Schedule-controlled behavior maintained by nitrous oxide delivery in the rhesus monkey. Proceedings of a Symposium on Drugs as Reinforcers. Excerpta Medica: International Congress Series. 620:1981;259-274.
22. Haertzen C.A. Development of scales based on patterns of drug effects, using the Addiction Research Center Inventory (ARCI). Psychol Rep. 18:1966;163-194.
23. Hargreaves K.M., Dionne R.A., Mueller G.P., Goldstein D.S., Dubner R. Naloxone, fentanyl, and diazepam modify beta-endorphin levels during surgery. Clin Pharmacol Ther. 40:1986;165-171.
24. Harper M.H., Winter P.M., Johnson B.H., Eger E.I. Naloxone does not antagonize general anesthesia in the rat. Anesthesiology. 49:1978;3-5.
25. Heishman S.J., Stitzer M.L., Bigelow G.E., Liebson I.A. Acute opioid physical dependence in postaddict humans: naloxone dose effects after brief morphine exposure. J Pharmacol Exp Ther. 248:1989;127-134.
26. Hoehn-Saric R., Masek B.J. Effects of naloxone on normals and chronically anxious patients. Biol Psychiatry. 16:1981;1041-1050.
27. Jasinski D.R., Martin W.R., Haertzen C.A. The human pharmacology and abuse potential of n-allylnoroxymorphone (naloxone). J Pharmacol Exp Ther. 157:1967;420-426.
28. Jastak J.T., Paravecchio R. An analysis of 1,331 sedations using inhalation, intravenous, or other techniques. J Am Dental Assoc. 91:1975;1242-1249.
29. Jevtovic-Todorovic V., Todorovic S.M., Mennerick S., Powell S., Dikranian K., Benshoff N., Zorumski C.F., Olney J.W. Nitrous oxide (laughing gas) is an NMDA antagonist, neuroprotectant and neurotoxin. Nature Med. 4:1998;460-463.
30. Judd L.L., Janowsky D.S., Segal D.S., Huey L.Y. Naloxone-induced behavioral and physiological effects in normal and manic subjects. Arch Gen Psychiatry. 37:1980;583-586.
31. Kumor K.M., Haertzen C.A., Jasinski D.R., Johnson R.E. The psychopharmacologic and prolactin response after large doses of naloxone in man. Pharamacol Biochem Behav. 30:1988;967-975.
32. Lawrence D., Livingston A. Opiate-like analgesic activity in general anaesthetics. Br J Pharmacol. 73:1981;435-442.
33. Levine J.D., Gordon N.C., Fields H.L. Naloxone dose-dependently produces analgesia and hyperalgesia in postoperative pain. Nature. 278:1979;740-741.
34. Levine J.D., Gordon N.C., Fields H.L. Naloxone fails to antagonize nitrous oxide analgesia for clinical pain. Pain. 13:1982;165-170.
35. Martin del Campo A.F., McMurray R.G., Besser G.M., Grossman A. Effect of 12-hour infusion of naloxone on mood and cognition in normal male volunteers. Biol Psychiatry. 32:1992;344-353.
36. Martin del Campo A.F., Dowson J.H., Herbert J., Paykel E.S. Effects of naloxone on diurnal rhythms in mood and endocrine function: a dose-response study in man. Psychopharmacology. 114:1994;583-590.
37. Martin del Campo A.F., Granados-Soto V., Aguirre-Banelos P., Cardenas M., Castaneda-Hernandez G. The use of the plasma-concentration effect relationship as a tool for the study of the mechanism of action of naloxone effects on mood and endocrine function. J Psychopharmacol. 11:1997;361-365.
38. Martin W.R., Sloan J.W., Sapira J.D., Jasinski D.R. Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin Pharmacol Ther. 12:1971;245-258.
39. Melzack R. The short-form McGill Pain Questionnaire. Pain. 30:1987;191-197.
40. Moody E.J., Mattson M., Newman A.H., Rice K.C., Skolnick P. Stereospecific reversal of nitrous oxide analgesia by naloxone. Life Sci. 44:1989;703-709.
41. Ohara A., Mashimo T., Zhang P., Inagaki Y., Shibuta S., Yoshiya I. A comparative study of the antinociceptive action of xenon and nitrous oxide in rats. Anesth Analg. 85:1997;931-936.
42. Pirec V., Patterson T., Thapar P., Apfelbaum J.L., Zacny J.P. Effects of subanesthetic concentrations of nitrous oxide on cold-pressor pain in humans. Pharmacol Biochem Behav. 51:1995;323-329.
43. Pirec V., Coalson D.W., Lichtor J.L., Klafta J., Young C., Rupani G., Apfelbaum J.L., Zacny J.P. Cold water immersion modulates the reinforcing effects of nitrous oxide in healthy volunteers. Exp Clin Psychopharmacol. 3:1995;148-155.
44. Preston K.L., Bigelow G.E., Liebson I.A. Antagonist effects of nalbuphine in opioid-dependent human volunteers. J Pharmacol Exp Ther. 248:1989;929-937.
45. Quock R.M., Emmanouil D.E., Vaughn L.K., Pruhs R.J. Benzodiazepine receptor mediation of behavioral effects of nitrous oxide in mice. Psychopharmacology. 107:1992;310-314.
46. Quock R.M., Curtis B.A., Reynolds B.J., Mueller J.L. Dose-dependent antagonism and potentiation of nitrous oxide antinociception by naloxone in mice. J Pharmacol Exp Ther. 267:1993;117-122.
47. Reisine T., Pasternak G. Opioid analgesics and antagonists. Hardman J.G., Gilman A.G., Limbird L.E. Goodman and Gilman's the pharmacological basis of therapeutics. 9th ed :1996;521-555 Pergamon, New York.
48. Schull J., Kaplan H., O'Brien C.P. Naloxone can alter experimental pain and mood in humans. Physiol Psychol. 9:1981;245-250.
49. Shingu K., Osawa M., Omatsu Y., Komatsu T., Urabe N., Mori K. Naloxone does not antagonize the anesthetic-induced depression of nociceptor-driven spinal cord response in spinal rats. Acta Anaesthiol Scand. 35:1981;526-532.
50. Smith R.A., Wilson M., Miller K.W. Naloxone has no effect on nitrous oxide anesthesia. Anesthesiology. 49:1978;6-8.
51. Stacher G., Abatzi T., Schulte F., Schneider C., Stacher-Janotta G., Gaupmann G., Mittelback G., Steinringer H. Naloxone does not alter the perception of pain induced by electrical and thermal stimulation of the skin in healthy humans. Pain. 34:1988;271-276.
52. Volavka J., Dornbush R., Mallya A., Cho D. Naloxone fails to affect short-term memory in man. Psychiatry Res. 1:1979;89-92.
53. Wechsler D. The measurement and appraisal of adult intelligence. 1958;Williams and Wilkins, Baltimore, MD.
54. Wolff B.B. Methods of testing pain mechanisms in normal man. Wall P.D., Melzack R. Textbook of pain. 1984;186-194 Churchill Livingstone, Edinburgh.
55. Yagi M., Mashimo T., Kawaguchi T., Yoshiya I. Analgesic and hypnotic effects of subanaesthetic concentrations of xenon in human volunteers: comparison with nitrous oxide. Br J Anaesth. 74:1995;670-673.
56. Yang J.C., Clark W.C., Ngai S.H. Antagonism of nitrous oxide analgesia by naloxone in man. Anesthesiology. 52:1980;414-417.
57. Zacny J.P., Coalson D.W., Lichtor J.L., Yajnik S., Thapar P. Effects of naloxone on the subjective and psychomotor effects of nitrous oxide in humans. Pharmacol Biochem Behav. 49:1994;573-578.
58. Zacny J., Yajnik S., Coalson D., Lichtor J.L., Thapar P., Apfelbaum J.L., Rupani G., Young C., Klafta J. Flumazenil may attenuate some subjective effects of nitrous oxide in humans: a preliminary report. Pharmacol Biochem Behav. 51:1995;815-819.
59. Zuniga J., Joseph S., Knigge K. Nitrous oxide analgesia: partial antagonism by naloxone and total reversal after periaqueductal gray lesions in the rat. Eur J Pharmacol. 142:1987;51-60.